YUHAN CORPORATION |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 72,500 KRW | +0.28% |
|
+0.14% | +5.38% |
| Apr. 24 | Korean Sugar Imports Plunge 14% as Diabetes Cases Surge | MT |
| Mar. 07 | Yuhan Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company's profit outlook over the next few years is a strong asset.
- The company is in a robust financial situation considering its net cash and margin position.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 34.11 times its estimated earnings per share for the ongoing year.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +5.38% | 3.97B | B- | ||
| +6.97% | 71.94B | A | ||
| -10.86% | 5.13B | A- | ||
| +46.43% | 4.66B | - | ||
| -16.20% | 2.55B | C- | ||
| +21.10% | 2.41B | B | ||
| -26.20% | 2.36B | - | ||
| +19.92% | 2.21B | - | - | |
| +8.15% | 1.71B | D+ | ||
| -0.50% | 1.64B | - | - |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- A000100 Stock
- Ratings Yuhan Corporation